Laquinimod in the treatment of relapsing remitting multiple sclerosis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 6, 2016, Pages 701-709

  Hainke, Undine ^a   Thomas, Katja ^a   Ziemssen, Tjalf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cytokines; demyelination; immunomodulation; laquinimod; MRI; neuroprotection

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; LAQUINIMOD; LIVER ENZYME; IMMUNOLOGIC FACTOR; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; APPENDICITIS; ARTHRALGIA; AXONAL INJURY; BACKACHE; BRAIN SIZE; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CLINICAL TRIAL (TOPIC); DEMYELINATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG LEGISLATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE NEURITIS; HEADACHE; HELPER CELL; HUMAN; MAXIMUM TOLERATED DOSE; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; ANIMAL; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; QUINOLONES;

EID: 84965047404     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1179279     Document Type: Review

References (41)

1. C.Bjartmar, G.Kidd, S.Mork, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893–901.
2. P.Ganter, C.Prince, C.Esiri, et al. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol. 1999;25:459–467.
3. W.Brück, R.Gold, B.T.Lund, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013;70(10):1315–1324.
4. T.Ziemssen, T.Derfuss, N.Stefano, et al. Optimizing treatment success in multiple sclerosis. J Neurol [Internet]. 2015 Dec 24. doi:10.1007/s00415-015-7986-y.
5. R.Haase, J.S.Kullmann, T.Ziemssen Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. TAND. 2016 Mar 15. DOI:10.1177/1756285616634247.
6. D.M.Karussis, D.Lehmann, S.Slavin, et al. Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol. 1993;34:654–660.
7. D.M.Karussis, D.Lehmann, S.Slavin, et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A. 1993;90:6400–6404.
8. J.H.Noseworthy, J.S.Wolinsky, F.D.Lublin, et al. Linomide in relapsing and secondary progressive MS: Part I. Trial design and clinical results. Neurology. 2000;54:1726–1733.
9. J.Wolinsky, P.Narayana, J.Noseworthy, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000;54(9):1734–1741.
10. O.Andersen, J.Lycke, P.O.Tollesson, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology. 1996;47:895–900.
11. I.L.Tan, G.J.Lycklmaà Nijeholt, C.H.Polman, et al. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase III trails. Mult Scler. 2000;6:99–104.
12. S.Jonsson, G.Andersson, T.Fex, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. Lund (Sweden): Active Biotech Research AB. J Med Chem. 2004;47(8):2075–2088.
13. C.Brunmark, A.Runström, L.Ohlsson, et al. The new orally active immunregulator laqunimod (ABR – 215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163–172.
14. D.R.Jeffery, E.Pharr, N.A.Zeid. Laquinimod in relapsing remitting multiple sclerosis. US Neurol. 2010;6(2):70–75.
15. J.Preiningerova. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs. 2009;18(7):985–989.
16. W.Brück, C.Wegner. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173–179. doi:10.1016/j.jns.2011.02.019.
17. Nerventra. European medicines agency; [cited 2014 May 22]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002546/WC500171788.pdf
18. R.Aharoni, R.Saada, R.Eilam, et al. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;251:14–24.
19. L.Zou, N.Abbas, I.Volkmann, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology. 2002;42:731–739.
20. M.Mishra, J.Wang, C.Silva, et al. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol. 2012;181:642–651.
21. M.Gurevich, T.Gritmann, R.Orbach, et al. Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol. 2010;221:87–94.
22. U.Schulze-Topphoff, A.Shetty, M.Varrin-Doyer, et al. Laqunimod, a quinoline 3 carboxamie, induces typ II myeloid cells that modulate central nervosus system autoimmunity. PLoS One. 2012;7(3):e33797.•• Evidence for modulation of primarily immune cells by laquinimod leading to suppressions of inflammation in the periphery and in the CNS.
23. W.Brück, R.Pförtner, T.Pham, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012;124:411–424.
24. S.Moore, A.Khalaj, J.Yoon, et al. Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav. 2013;3(6):664–682.•• Evidence for increase of the potential for remyelination by laquinimod.
25. J.Thöne, G.Ellrichmann, S.Seubert, et al. Modulation of autoimmune demyelination by laqunimod via induction of brain derived neurotrophic factor. Am J Pathol. 2012;180:267–274.•• Evidence that brain derived neurotrophic factor mediates some of the neuroprotective properties of laquinimod in vivo.
26. C.Wegner, C.Stadelmann, R.Pförtner, et al. Laqunimod interferes with migratory capacity of T cells and reduces IL 17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133–143.
27. E.Toubi, S.Nussbaum, E.Staun-Ram, et al. Laqunimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol. 2012;251:45–54.
28. V.Jolivel, F.Luessi, J.Masri, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain J Neurol. 2013;136(4):1048–1066.•• Evidence for modulation of the innate immune system of laquinimod as essential mechanism for suppression of multiple sclerosis.
29. B.Lund, E.Kelland, L.Hayardeny, et al. Assessment of changes in immune measures of multiple sclerosis patients treated with laqunimod. J Neuroimmunol. 2013;263:108–115.
30. E.Kelland, W.Gilmore, L.Hayardeny, et al. In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells. J Neurol Sci. 2014;346:66–74.
31. C.Polman, F.Barkhof, M.Sandberg-Wollheim, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64(6):987–991.• The first phase 2 trial of laquinimod in patients with RRMS presenting positive results on the primary outcome measure.
32. G.Comi, M.Rovaris, O.Abramsky, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085–2092.• A phase 2 trial confirming the therapeutic effects and benefits of laquinimod.
33. G.Comi, O.Abramsky, T.Arbizu, et al. Oral laquinimod in patients with relapsing-remitting multiple sclersosis: 36 week double-blind extension of the multi-centre, randomized, double –blind, parallel-group placebo-controlled study. Mult Scler. 2010;16(11):1360–1366.
34. G.Comi, D.Jeffery, L.Kappos, et al. Placebo controlled trial of oral laquinimod for multiple sclerosis. N Eng J Med. 2012;366:1000–1009.•• A phase 3 trial showing more potential effects of laquinimod in preventing disability progression than in decreasing risk of relapses.
35. M.Filippi, M.A.Rocca, E.Pagani, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg and Psych. 2013;85(8):851–859.
36. T.L.Vollmer, P.S.Sorenson, K.Selmaj, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773–783.
37. H.Tumani, T.Ziemssen, F.Paul, et al. Safety and tolerability of escalating doses of laquinimod, an oral immunomodulatory agent in development for treatment of relapsing-remitting multiple sclerosis. Tracking Number 14-A-514-AAN.
38. clinicaltrials.gov. The efficacy and safety and tolerability of laqunimod in subjects with relapsing remitting multiple sclerosis (RRMS) (CONCERTO) [Internet]. [cited 2016 Jan 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT01707992
39. clinicaltrials.gov. A phase 2 clinical study in subjects with primary progressive multiple sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.5mg/day (experimental drug) as compared to placebo [Internet]. [cited 2016 Jan 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02284568
40. Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials. CONCERTO and ARPEGGIO trials continue study of lower-dose laquinimod [Internet]. [cited 2016 Jan 2]. Available from: http://www.tevapharm.com/news/teva_and_active_biotech_announce_discontinuation_of_higher_doses_of_laquinimod_in_two_multiple_sclerosis_trials_01_16.aspx
41. Refusal of the marketing authorization for Nerventra (laquinimod). European medicines agency. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002546/WC500160120.pdf